Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Complete Title: An Open-Label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Enitociclib
(VIP152) Monotherapy or Combination Therapy in Subjects with High-Risk Chronic Lymphocytic Leukemia or Richter Syndrome
Trial Phase: I
Investigator: Mazyar Shadman
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome
Keywords:
- Leukemia, Chronic Lymphocytic (CLL)
- Lymphoma, Non-Hodgkin (NHL)
- Richter Syndrome
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Mazyar Shadman
RG1122165
NCT04978779
An Open-Label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Enitociclib
(VIP152) Monotherapy or Combination Therapy in Subjects with High-Risk Chronic Lymphocytic Leukemia or Richter Syndrome
Leukemia, Chronic Lymphocytic (CLL)
Lymphoma, Non-Hodgkin (NHL)
Richter Syndrome